OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI acquired Orchestra Bio, a startup that helps pharmaceutical teams coordinate drug development, and integrated it into the life sciences platform Rosalind. Orchestra's agents are used to track trials, flag timelines affected by issues like production batch failures, and provide follow-up options. OpenAI states that developing a drug in the US takes an average of 10 to 15 years, and the transaction amount was not disclosed.
Same story1 other outlet also reported this
- TechCrunch · AI··First
- The Decoder··+11 h 58 min·Reading now
OpenAI acquires Orchestra Bio to build AI agents for accelerating drug discovery
Adds:OpenAI mentions the average time to develop a drug in the US is 10 to 15 years.
In order of publication · later reports are added as they appear · Compared by AI from each outlet’s title and summary
OpenAI is making a bigger bet on pharmaceuticals. The company acquired Orchestra Bio, a startup that helps pharma teams coordinate drug development. Orchestra will be folded into Rosalind, OpenAI's AI platform for life sciences. GPT-Rosalind helps researchers analyze biological and chemical questions, while Rosalind Workbench connects those capabilities with scientific data and tools.
The combined effort aims to build AI agents that link scientific findings with clinical trials, decisions, and next steps to get new drugs to patients faster. Developing a drug in the US takes ten to 15 years on average. Beyond the scientific hurdles, siloed systems and the constant back-and-forth between internal teams and outside partners slow things down.
Orchestra's agents are designed to take work off teams' plates by tracking trials, flagging affected timelines when something goes wrong like a failed production batch, and surfacing options for what to do next. That could free scientists to focus on decisions and the actual research. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research. Financial terms of the deal weren't disclosed.
AI News Without the Hype – Curated by Humans
Subscribe to THE DECODER for ad-free reading, a weekly AI newsletter, our exclusive "AI Radar" frontier report six times a year, full archive access, and access to our comment section.
Source: The Decoder · the-decoder.com